Analyst Ratings For Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
Today, JMP Securities reiterated its Buy rating on Enanta Pharmaceuticals Inc (NASDAQ:ENTA) with a price target of $120.00.
There are 3 Hold Ratings, 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is Buy with a consensus target price of $90.3333 per share, a potential 7.70% downside.
Some recent analyst ratings include
- 7/31/2018-JMP Securities Reiterated Rating of Buy.
- 6/7/2018-Oppenheimer initiated coverage with a Buy rating.
- 6/6/2018-Roth Capital initiated coverage with a Buy rating.
- 4/4/2018-Royal Bank of Canada Reiterated Rating of Hold.
- 2/8/2018-JPMorgan Chase & Co. was Downgraded by analysts at JPMorgan Chase & Co. from a “Overweight ” rating to a ” Neutral” rating. They now have a N/A price target on the stock.
Recent Insider Trading Activity For Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has insider ownership of 10.56% and institutional ownership of 77.06%.
- On 7/18/2018 Nathalie Adda, VP, sold 5,045 with an average share price of $124.84 per share and the total transaction amounting to $629,817.80.
- On 7/6/2018 Jay R Luly, Insider, sold 35,000 with an average share price of $125.24 per share and the total transaction amounting to $4,383,400.00.
- On 6/18/2018 Nathalie Adda, VP, sold 4,155 with an average share price of $114.85 per share and the total transaction amounting to $477,201.75.
- On 6/11/2018 Paul J Mellett, Treasurer, sold 15,000 with an average share price of $120.57 per share and the total transaction amounting to $1,808,550.00.
- On 5/17/2018 Jay R Luly, Insider, sold 25,000 with an average share price of $105.83 per share and the total transaction amounting to $2,645,750.00.
- On 5/16/2018 Nathalie Adda, VP, sold 4,155 with an average share price of $105.25 per share and the total transaction amounting to $437,313.75.
- On 4/16/2018 Nathalie Adda, VP, sold 4,225 with an average share price of $85.58 per share and the total transaction amounting to $361,575.50.
About Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Recent Trading Activity for Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
Shares of Enanta Pharmaceuticals Inc closed the previous trading session at 98,66 up +1,28 1,31 % with shares trading hands.